Injectable biopolymer compositions and associated systems and methods are disclosed herein. In some embodiments, a biopolymer composition for treating an aneurysm is provided. The biopolymer composition can include an injectable hydrogel including: a biopolymer; a chemical crosslinker forming covalent bonds with the biopolymer; and a stabilizer configured to inhibit ex vivo precipitation of the biopolymer. The injectable hydrogel can have an ex vivo storage modulus of at least 100 Pa at 37° C. over a linear viscoelastic region of the injectable hydrogel. The ex vivo storage modulus can be greater than an ex vivo loss modulus of the injectable hydrogel over the linear viscoelastic region of the injectable hydrogel.

The present disclosure pertains to crosslinkable compositions and systems as well as methods for forming crosslinked compositions in situ, including the use of the same for controlling the movement of bodily fluid within a patient, among many other uses.

Hydrogel compositions prepared from amine components and glycidyl ether components are provided which are biocompatible and suitable for use in vivo due, in part, to their excellent stability.

Described herein are polymers and associated methods to occlude structures and malformations of the vasculature with polymers with delayed controlled rates of expansion. Methods of forming such devices are also disclosed.

In some aspects, the disclosure pertains to injectable particles that contain at least one pH-altering agent that is configured to be released from the injectable particles in vivo, upon embolization of an intratumoral artery of a tumor with the injectable particles. In certain instances, the pH altering agent may be a basic agent having a pH value of 7.5, a buffering agent having a pKa value of 7.6 or more, or both. Other aspects of the disclosure pertain to preloaded containers containing such injectable particles and methods of using such injectable particles.

Embolic particles are described. The particles are reaction products of a prepolymer solution including at least one polyether macromer and an appropriate monomer.

The present invention is directed to hemostatic compositions comprising at least partially integrated agglomerated ORC fibers, fibrinogen, and thrombin and methods of forming a powdered hemostatic composition, comprising the steps of: forming a suspension of a mixture comprising particles of fibrinogen, thrombin, ORC fibers in a non-aqueous low boiling solvent; spraying the suspension through a nozzle onto a substrate, allowing the non-aqueous solvent to evaporate; separating from the substrate and sieving the composition.

A composite viscoelastic hydrogel comprises a continuous phase of non-crosslinked hyaluronic acid gel and a dispersed phase of dehydrothermally-crosslinked micron-sized gelatin hydrogel particles. The hydrogel exhibits a storage modulus (G′) of greater than 400 Pa and a tan δ (G″/G′) from 0.1 to 0.8 in dynamic viscoelasticity measured by a rheometer at 1 Hz and 1% strain rate at 25° C. The dehydrothermally crosslinked micron-sized gelatin hydrogel particles have an average dimension of less than 100 microns prior to hydration.

Provided are the use of poly(N-isopropylacrylamide-co-butyl methacrylate) in preparing an embolism material for blood vessels, an embolism material for blood vessels and the use thereof in preparation of drugs. The embolism material for blood vessels comprises poly(N-isopropylacrylamide-co-butyl methacrylate) and a dispersion medium consisting of an electrolyte, a contrast agent, a pH regulator and water. The concentrations of the polymer, electrolyte and contrast agent are respectively 5-30 mg/ml, 0.1-30 mg/ml and 100-350 mg/ml based on iodine. The embolism material for blood vessels is suitable for embolization therapy of tumors in hypervascular and parenchymal visceral organs.

Systems, methods and compositions relating to delivering synthetic polymer formulations to the body are described, which can be used by a range of medical personnel including those with minimal experience and training. Under some embodiments, the present invention relates to systems and devices for delivering polymer formulations to a body cavity (e.g. peritoneal cavity) to reduce or stop bleeding. Under some embodiments, an initial percutaneous access pathway is first formed using a delivery device with a probe and needle mechanism that automatically stops the advance of the device upon insertion into a body cavity or space, thus minimizing user error and improving patient safety. The hollow probe then allows transmission of polymer, mixed with gas and/or additional substances, from a holding chamber or canister to flow through the device and hollow probe into the patient's anatomic cavity or space of interest, stopping expansion when the device senses the appropriate pressure. Once reaching the body cavity, the polymer formulation functions to reduce and/or stop bleeding.